Viral Hepatitis Prevention Priorities

For Everyone

At a glance

The Division of Viral Hepatitis (DVH) 2030 Strategic Plan articulates vision, mission, core values, and goals. Each goal is further defined by specific and time-bound outcome measures and supporting objectives and associated strategies.

Division of Viral Hepatitis

About the viral hepatitis strategic plan

Vision

A world free from viral hepatitis

Mission

To eliminate viral hepatitis through leadership in science, partnerships, and public health practices

Goals

  1. Prevent new viral hepatitis infections
  2. Reduce viral hepatitis related morbidity and mortality
  3. Reduce viral hepatitis related disparities
  4. Improve viral hepatitis surveillance for public health action

Objectives and indicators of progress

Baseline, 2025 goals, 2030 goals

Category Baseline 2025 Goals 2030 Goals Approximate %
↓ or ↑*
for 2025/2030
Goal 1: Prevent new viral hepatitis infections (estimated cases)
Hepatitis A 6,700 ≤ 4,000 ≤ 2,500 ↓40%/↓65%
Acute hepatitis B 22,200 ≤ 18,000 ≤ 2,200 ↓20%/↓90%
Acute hepatitis C 44,700 ≤ 35,000 ≤ 4,400 ↓20%/↓90%
Goal 2: Reduce viral hepatitis related morbidity and mortality (reported death rates)
Hepatitis B-related 0.46 ≤ 0.37 ≤ 0.16 ↓20%/↓65%
Hepatitis C-related 4.13 ≤ 3.00 ≤ 1.44 ↓25%/↓65%
Goal 3: Reduce viral hepatitis related disparities (reported case rates)
Acute hepatitis B,
PWID≠		 1.4 ≤ 1.0 ≤ 0.1 ↓30%/↓90%
Hepatitis B-related
deaths, n-H A/PI		 2.45 ≤ 1.84 ≤ 0.86 ↓25%/↓65%
Acute hepatitis C,
PWID≠		 2.3 ≤ 1.7 ≤ 0.2 ↓25%/↓90%
Hepatitis C-related
deaths, n-H AI/AN		 10.24 ≤ 7.17 ≤ 3.58 ↓30%/↓65%
Hepatitis C-related
deaths, n-H/B		 7.03 ≤ 4.92 ≤ 2.46 ↓30%/↓65%
Indicators of Progress
2.1: % Hepatitis B
aware of infection		 32%
(2013–2016)		 ≥ 50%
(2021–2024)		 ≥ 90%
(2025–2028)		 ↑55% (2021–2024)/
↑180% (2025–2028)
2.4: % Hepatitis C
viral clearance		 43%
(2013–2016)		 ≥ 58%
(2021–2024)		 ≥ 80%
(2025–2028)		 ↑35% (2021–2024)/
↑85% (2025–2028)

Note: Unless otherwise noted, baseline data are from 2017, 2025 goals are based on 2023 data, and 2030 goals are based on 2028 data. Rates are per 100,000 population.
*Reductions are compared to 2017, unless otherwise noted.
≠18–40-year-olds serve as a proxy for persons who inject drugs (PWID).
n-H A/PI = non-Hispanic Asian and Pacific Islander persons; n-H AI/AN = non-Hispanic American Indian and Alaska Native persons; n-H/B = non-Hispanic Black persons

Data sources

Outcome / Indicator of Progress* Hepatitis Virus Data Source Data Year(s) Utilized
Baseline 2025 Goals 2030 Goals
New infections A, B, C NNDSS 2017 2023 2028
Deaths B, C NVSS 2017 2023 2028
Awareness of infection B NHANES 2013–2016 2021–2024 2025–2028
NNDSS = National Notifiable Diseases Surveillance System; NVSS = National Vital Statistics System; NHANES = National Health and Nutrition Examination Survey. *Indicators of Progress are quantitative measures available for certain objectives.
Print
Content Source
National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention
About This Page
Published: May 15, 2024
Updated: August 7, 2026

This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.

Reviewed: August 7, 2026

The information on this page was last reviewed by subject matter experts to ensure accuracy.

  • * 18-40 year-olds serve as a proxy for PWID
  • n-H AI/AN = non-Hispanic American Indian and Alaska Native Persons
  • n-H A/PI = non-Hispanic Asian and Pacific Islander persons
  • n-H/B = non-Hispanic Black persons
  • PWID = people who inject drugs